arch
bronconeumol
xxx
xx
xxxxxx
w
w
w
r
c
h
b
r
n
c
n
e
u
l
r
g
origin
articl
b
r
c
background
exacerb
crucial
event
bronchiectasi
progress
object
explor
associ
bacteri
viral
bacteri
plu
viral
isol
bronchiectasi
exacerb
method
prospect
studi
enrol
patient
follow
everi
month
onset
exacerb
march
novemb
spontan
sputum
split
detect
bacteria
routin
cultur
virus
quantit
polymeras
chain
reaction
symptom
lung
function
assess
exacerb
result
median
exacerb
rate
interquartil
rang
per
patientyear
visit
viral
isol
v
occur
frequent
onset
exacerb
odd
ratio
confid
interv
ci
isol
new
bacteria
nb
ci
bacteri
plu
viral
isol
ci
whilst
coryza
appear
common
exacerb
v
exacerb
pathogen
isol
nb
lower
airway
symptom
sever
exacerb
nb
p
sputum
level
higher
exacerb
nb
exacerb
pathogen
isol
v
p
significantli
coryza
symptom
correl
bacteri
plu
viral
isol
exacerb
p
compar
v
alon
bacteri
without
viral
isol
tend
yield
sever
lower
airway
symptom
sputum
cytokin
level
exacerb
conclus
viral
isol
isol
new
bacteria
bacteri
plu
viral
isol
associ
bronchiectasi
exacerb
symptom
exacerb
might
inform
clinician
possibl
culprit
pathogen
page
cl
chen
et
al
arch
bronconeumol
xxx
xx
xxxxxx
resultado
la
mediana
de
la
tasa
de
fue
de
rango
intercuartil
por
en
cualquier
visita
lo
aislamiento
de
viru
v
tuvieron
lugar
con
mayor
frecuencia
durant
el
inicio
de
la
exacerbacion
odd
ratio
intervalo
de
confianza
del
ic
al
igual
que
el
aislamiento
de
nueva
bacteria
nb
ic
lo
aislamiento
de
bacteria
viru
junto
ic
mientra
que
la
coriza
en
la
exacerbacion
con
v
que
en
la
exacerbacion
sin
aislamiento
de
en
aquella
con
nb
lo
de
la
respiratoria
inferior
fueron
grave
en
la
exacerbacion
con
nb
p
lo
nivel
de
en
el
esputo
fueron
alto
en
la
exacerbacion
con
nb
que
en
la
exacerbacion
sin
aislamiento
de
aquella
con
v
ambo
p
de
manera
significativa
de
coriza
se
correlacionaron
con
aislamiento
de
bacteria
viru
junto
durant
la
exacerbacion
p
comparado
con
lo
v
en
solitario
lo
aislamiento
de
bacteria
con
sin
viru
tienden
producir
grave
en
la
respiratoria
inferior
pero
alteran
lo
nivel
de
citocina
en
el
esputo
durant
la
exacerbacion
conclusion
lo
aislamiento
de
viru
el
aislamiento
de
nueva
bacteria
el
aislamiento
de
bacteria
viru
junto
asociado
la
exacerbacion
de
la
bronquiectasia
lo
de
la
exacerbacion
pueden
proporcionar
lo
sobr
lo
posibl
respons
r
e
u
e
n
contexto
la
exacerbacion
son
evento
crucial
durant
la
de
la
bronquiectasia
objetivo
analizar
la
asociacion
entr
el
aislamiento
de
bacteria
viru
viru
bacteria
junta
la
exacerbacion
de
la
bronquiectasia
en
est
estudio
prospectivo
se
pacient
lo
que
se
cada
mese
al
comienzo
de
la
exacerbacion
entr
marzo
de
noviembr
de
la
muestra
de
esputo
se
para
la
de
bacteria
cultivo
de
rutina
viru
en
cadena
de
la
polimerasa
cuantitativa
se
evaluaron
lo
la
pulmonar
durant
la
exacerbacion
bronchiectasi
debilit
chronic
airway
inflammatori
diseas
aggrav
bacteri
andor
viral
infect
acut
exacerb
ae
critic
event
associ
consider
morbid
mortal
contribut
significantli
impair
qualityoflif
understand
role
pathogen
may
help
diagnos
identifi
target
intervent
infect
frequent
associ
ae
dilat
bronchi
becom
nich
bacteria
virus
fungi
virus
frequent
isol
ae
bronchiectasi
detect
rate
signific
chang
total
bacteri
densiti
microbi
composit
observ
ae
nevertheless
antibiot
remain
princip
effect
manag
ae
suggest
bacteri
isol
might
aggrav
inflammatori
respons
accumul
evid
demonstr
interact
pathogen
bacteria
virus
hostdefens
chronic
airway
inflammatori
diseas
bacteri
plu
virus
eg
nontyp
haemophilu
influenza
rhinoviru
isol
frequent
detect
chronic
obstruct
pulmonari
diseas
copd
exacerb
stabl
state
correl
sever
copd
exacerb
role
bacteria
virus
bronchiectasi
report
separ
prospect
studi
investig
impact
bacteri
plu
viral
isol
adult
bronchiectasi
moreov
symptom
could
differenti
bacteri
viral
bacteri
plu
viral
isol
exacerb
entir
clear
aim
explor
associ
bacteri
viral
isol
ae
investig
clinic
characterist
could
indic
possibl
pathogen
isol
ae
observ
singlecent
prospect
studi
recruit
bronchiectasi
patient
age
year
outpati
clinic
first
affili
hospit
guangzhou
medic
univers
march
novemb
bronchiectasi
diagnos
accord
chest
highresolut
comput
tomographi
review
experienc
radiologist
compat
clinic
symptom
eg
chronic
cough
sputum
product
elig
patient
remain
clinic
stabl
respiratori
symptom
exceed
normal
daili
variat
use
antibiot
except
lowdos
macrolid
four
week
activ
tuberculosi
malign
acut
respiratori
tract
infect
within
four
week
asthma
copd
primari
diagnosi
exclud
studi
protocol
approv
ethic
committe
first
affili
hospit
guangzhou
medic
univers
medic
ethic
patient
sign
inform
consent
initi
visit
clinic
evalu
includ
demographi
clinic
histori
spirometri
exacerb
rate
within
preced
month
blood
sputum
collect
spirometri
perform
accord
intern
guidelin
radiolog
sever
assess
modifi
reiff
score
diseas
sever
calcul
bronchiectasi
sever
index
bsi
efac
score
patient
follow
interv
novemb
multipl
visit
request
contact
investig
upon
signific
worsen
symptom
addit
visit
schedul
within
h
antibiot
use
exceed
h
upper
limit
durat
symptom
onset
day
day
confirm
symptom
onset
ae
visit
symptom
questionnair
see
onlin
supplement
queri
upper
lower
airway
symptom
rate
sever
visual
analog
scale
va
rang
spirometri
sputum
blood
specimen
obtain
followup
includ
stabl
visit
ae
visit
ae
defin
signific
deterior
h
symptom
includ
cough
frequenc
sputum
volum
andor
consist
sputum
purul
breathless
andor
exercis
toler
fatigu
andor
malais
hemoptysi
requir
immedi
chang
treatment
treatment
decis
made
test
result
becam
avail
detail
shown
onlin
supplement
briefli
patient
thoroughli
rins
mouth
follow
deep
cough
collect
spontan
sputum
sputum
plug
purul
portion
select
elig
sampl
leukocytesepitheli
cell
uniform
techniqu
chest
physiotherapi
employ
sputum
immedi
split
bacteri
cultur
viral
detect
multiplex
quantit
polymeras
chain
reac
tion
qpcr
ultracentrifug
g
h
c
sputum
sol
prepar
storag
c
inflammatori
biomark
cxc
motif
tumor
necrosi
multiplex
assay
describ
previous
bacteri
viral
detect
bacteri
cultur
homogen
fresh
sputum
sputasol
oxoid
uk
follow
inocul
blood
chocol
agar
plate
biomeurix
inc
franc
overnight
incub
pathogen
bacteria
includ
limit
pseudomona
aeruginosa
haemophilu
influenza
haemophilu
parainfluenza
klebsiella
pneumonia
streptococcu
pneumonia
streptococcu
aureu
escherichia
coli
isol
new
bacteria
denot
sputum
cultur
find
switch
neg
posit
pathogen
bacterium
anoth
pathogen
bacterium
extract
viral
nucleic
acid
use
extract
kit
takara
minibest
viral
rnadna
extract
kit
ver
conduct
qpcr
base
taqman
tm
probe
identifi
sixteen
common
respiratori
virus
rhinoviru
influenza
viru
ab
parainfluenza
viru
human
coronaviru
respiratori
syncyti
viru
adenoviru
enteroviru
bocaviru
human
metapneumoviru
valid
viral
detect
kit
purchas
guangzhou
huyansuo
medic
technolog
co
ltd
guangzhou
china
cycl
threshold
ct
consid
posit
lower
ct
indic
higher
viral
load
data
exist
regard
proport
patient
bacteri
plu
viral
isol
bronchiectasi
assum
equival
proport
patient
bacteri
isol
stablest
ae
differ
viru
detect
rate
ae
stablest
bronchiectasi
patient
would
need
base
twosid
signific
power
take
account
dropout
rate
data
express
mean
standard
deviat
median
interquartil
rang
iqr
continu
variabl
count
percentag
categor
variabl
gener
estim
equat
logit
link
use
explor
associ
pathogen
isol
odd
ae
compar
stabl
visit
take
account
repeat
observ
individu
particip
continu
variabl
analyz
ttest
analysisofvari
mannwhitney
kruskalw
test
depend
variabl
distribut
categor
variabl
compar
chisquar
fisher
exact
test
miss
valu
imput
statist
analysi
perform
use
spss
spss
inc
chicago
usa
graphpad
prism
version
graphpad
inc
usa
patient
screen
patient
enrol
followedup
fig
median
followup
durat
month
patient
provid
sputum
sampl
stablevisit
ae
median
iqr
sputum
specimen
per
patient
seventythre
patient
experienc
least
one
ae
report
ae
followup
ae
sampl
contact
late
declin
due
avail
administ
antibiot
day
yield
sputum
sputum
mostli
sampl
antibiot
administr
ae
except
sampl
sampl
within
h
antibiot
administr
clinic
characterist
differ
patient
provid
sputum
ae
tabl
patient
characterist
full
ae
cohort
shown
tabl
mean
age
year
median
bsi
iqr
efac
score
iqr
common
etiolog
postinfect
tuberculosi
asthma
primari
etiolog
eight
patient
percentag
pathogen
detect
bacteri
isol
viral
detect
bacteri
plu
viral
detect
respect
stablevisit
correspond
percentag
respect
ae
p
fig
stablevisit
sampl
ae
sampl
test
posit
bacteria
p
three
preval
speci
isol
stablevisit
ae
sampl
pseudomona
aeruginosa
vs
haemophilu
influenza
vs
escherichia
coli
vs
note
yr
year
forc
expiratori
volum
data
present
mean
standard
deviat
median
interquartil
rang
n
aetiolog
includ
kartagen
syndrom
asthmaassoci
condit
gastrooesophag
reflux
diseas
diffus
panbronchiol
connect
tissu
diseas
cystic
fibrosi
transmembran
conduct
regulatorrel
diseas
congenit
lung
maldevelop
none
studi
particip
receiv
inhal
antibiot
studi
none
studi
particip
physiciandiagnos
cystic
fibrosi
howev
note
higher
detect
rate
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
ae
overal
bacteri
composit
took
account
bacteri
speci
differ
remark
stablevisit
ae
p
fig
proport
patient
test
posit
viru
increas
stablevisit
ae
p
preval
virus
includ
coronaviru
herp
simplex
viru
influenza
stablevisit
influenza
b
coronaviru
rhinoviru
ae
viral
spectrum
alon
differ
stablevisit
ae
p
dual
viral
speci
detect
ae
episod
tabl
patient
provid
ae
sputum
sampl
ident
viru
detect
wherea
ident
colon
bacteria
isol
patient
among
sputum
sampl
isol
bacteria
alon
correl
ae
p
fig
baselin
pathogen
includ
haemophilu
influenza
isol
statu
fail
predict
futur
risk
ae
followup
tabl
neither
bacteri
viral
isol
alon
baselin
predict
shorter
time
next
ae
followup
fig
collect
sampl
warmer
mayoctob
colder
season
novemberapril
detect
rate
virus
differ
significantli
vs
p
howev
note
signific
differ
rate
bacteri
isol
vs
p
rate
isol
new
bacteria
vs
p
fig
next
stratifi
patient
ae
pseudomona
ozana
n
staphylococcu
aureu
n
haemophilu
haemolyticu
n
haemophilu
parahaemolyticu
n
streptococcu
pneumonia
n
shewanella
alga
n
actinomyc
urea
n
pasteurella
multocida
n
enterobact
aerogen
n
serratia
marcescen
n
patient
isol
two
bacteria
clinic
stabl
henc
overal
percentag
patient
isol
pathogen
bacteria
appear
higher
clinic
stabl
compar
ae
onset
simultan
detect
viru
new
bacteria
demograph
clinic
characterist
differ
among
subgroup
tabl
symptom
questionnair
obtain
ae
viral
ae
tend
yield
coryza
symptom
unexplain
ae
new
bacteri
ae
p
tabl
neither
number
va
lower
airway
symptom
differ
among
three
group
stablevisit
fig
howev
increas
sputum
purul
mean
differ
va
breathless
mean
differ
va
deterior
notabl
new
bacteri
ae
fig
c
spirometri
assess
ae
lung
function
declin
differ
among
viral
new
bacteri
unexplain
ae
figur
sputum
cytokin
total
leukocyt
count
detect
ae
respect
median
level
increas
significantli
new
bacteri
ae
unexplain
ae
p
viral
ae
p
tumor
necrosi
level
except
comparison
viral
ae
p
new
bacteri
ae
trend
toward
higher
blood
neutrophil
count
viral
ae
yield
higher
monocyt
count
fig
investig
characterist
bacteri
plu
viral
isol
ae
divid
bacteriavirus
detect
n
bacteria
detect
alon
n
virus
detect
alon
n
bacteria
virus
detect
bv
n
coryza
symptom
bv
group
group
median
vs
p
ocular
itch
appear
frequent
bv
group
group
tabl
va
cough
sputum
sputum
purul
tend
higher
bv
group
p
trend
fig
greatest
lung
function
declin
p
trend
forc
vital
capac
note
group
fig
howev
notabl
amonggroup
differ
sputum
inflammatori
biomark
level
p
fig
first
studi
evalu
bacteri
plu
viral
infect
adult
bronchiectasi
isol
new
pathogen
bacteria
viral
isol
associ
ae
pathogen
isol
clinic
stabl
predict
futur
risk
ae
bacteri
plu
viral
isol
occur
frequent
ae
coryza
symptom
frequent
viral
ae
bacteri
plu
viral
isol
correl
greater
respiratori
symptom
burden
airway
inflamm
lung
function
impair
compar
bacteri
viral
isol
alon
nextgener
sequenc
appli
bronchiectasi
appli
routin
cultur
detect
bacteria
pcr
assay
detect
viru
method
simpl
accur
reliabl
wide
use
clinic
practic
furthermor
bacteria
detect
cultur
indic
viabil
andor
virul
henc
routin
techniqu
could
appli
pointofcar
test
realworld
practic
consist
previou
find
copd
exacerb
isol
new
bacteri
strain
classswitch
associ
ae
account
ae
warrant
antibiot
treatment
howev
total
bacteri
load
microbiota
taxa
analyz
rdna
sequenc
chang
unremark
antibiot
treatment
ae
intriguingli
isol
new
bacteri
strain
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
associ
increas
risk
copd
exacerb
studi
show
isol
new
bacteria
mainli
haemophilu
influenza
associ
ae
bronchiectasi
implic
pseudomona
aeruginosa
culprit
ae
antibiot
therapi
target
emerg
bacteri
speci
would
warrant
henc
rapid
microbiolog
assess
import
clinic
practic
may
help
avoid
overtreat
undertreat
viral
isol
occur
frequent
ae
viral
detect
rate
lower
previous
report
sourc
sampl
sputum
vs
nasopharyng
aspir
vs
sputum
plu
nasopharyng
swab
characterist
bronchiectasi
patient
might
contribut
differ
preval
virus
influenza
ab
coronaviru
rhinoviru
popul
congruent
find
copd
patient
hong
kong
influenza
ab
rhinoviru
coronaviru
play
crucial
role
ae
howev
mechan
underli
observ
unclear
warrant
investig
overal
find
mirror
report
adult
children
compar
studi
mitchel
et
al
differ
viral
spectrum
could
result
differ
detect
method
assay
kit
posit
threshold
ct
valu
geograph
region
confirm
bacteri
plu
viral
isol
occur
frequent
ae
stablevisit
interestingli
bacteri
plu
viral
isol
associ
greater
lung
function
impair
airway
inflamm
bacteri
viral
isol
alon
ae
contrast
bacteri
plu
viral
isol
yield
greater
lung
function
impair
heighten
inflammatori
respons
copd
exacerb
might
bacteri
plu
viral
isol
frequent
compris
pseudomona
aeruginosa
viral
isol
bronchiectasi
oppos
haemophilu
influenza
viral
isol
copd
inde
viral
isol
may
induc
secondari
bacteri
isol
aggrav
inflamm
howev
load
pseudomona
aeruginosa
increas
significantli
regardless
viral
isol
statu
diseas
statu
exacerb
vs
steadyst
cystic
fibrosi
moreov
respiratori
syncyti
viru
isol
reportedli
enhanc
pseudomona
aeruginosa
biofilm
growth
render
pseudomona
aeruginosa
infect
sustain
collect
pseudomona
aeruginosa
isol
unlik
trigger
ae
despit
coexist
viral
isol
bronchiectasi
first
studi
analyz
associ
symptom
ae
bronchiectasi
would
help
clinician
rapidli
identifi
possibl
culprit
coryza
symptom
indic
viral
isol
fever
ubiquit
differ
type
ae
henc
viral
ae
judg
base
fever
alon
ae
associ
new
occurr
bacteria
yield
sever
lower
airway
symptom
heighten
airway
inflammatori
respons
therefor
clinician
vigil
identif
manag
antibiot
appropri
limit
consid
recruit
dri
bronchiectasi
patient
still
might
ae
attribut
pathogen
infect
sampl
size
insuffici
power
subgroup
analys
blood
test
spirometri
avail
patient
declin
due
repeat
assess
poor
overal
wellb
ae
captur
half
ae
episod
although
clinic
characterist
patient
differ
whose
ae
captur
furthermor
measur
bacteri
load
reportedli
chang
insignificantli
ae
ae
manag
outpati
clinic
henc
find
might
extrapol
sever
ae
need
hospit
virus
detect
ae
might
pathogen
howev
gee
model
reveal
associ
pathogen
isol
ae
final
find
symptom
associ
viral
bacteri
isol
specif
bronchiectasi
howev
studi
would
still
inform
find
help
clinician
infer
possibl
culprit
pathogen
assay
becam
avail
summari
build
previou
public
current
studi
provid
import
clinic
insight
isol
new
bacteria
viral
isol
bacteri
plu
viral
isol
associ
ae
bronchiectasi
studi
determin
caus
unexplain
ae
need
